Rochester, Minn., Nov 18, 2016 – Dynasil Corporation of America (NASDAQ: DYSL) today announced that it has made a commitment for a further $1.2 million investment in subsidiary Xcede Technologies, Inc. This investment comes alongside a commitment from Cook Biotech Inc. (CBI) of West Lafayette, Ind., to manage the Xcede Patch first-in-human clinical study on behalf of Xcede in exchange for secured loan considerations of up to $1.5 million. In addition, Peter Sulick, Dynasil Chairman and CEO, and members of his family made an additional investment of $450,000. It is anticipated this $3.15 million funding will be sufficient for Xcede to complete first-in-human clinical trials and related preclinical tests. The preclinical studies are anticipated to begin in 2016 and the trial in 2017.

Newton, MA., November 2, 2016 – Dynasil Corporation of America (NASDAQ: DYSL) today announced that its subsidiary, RMD Inc., will be supplying Thermo Fisher Scientific with packaged solid state detectors based on RMD’s Cs2LiYCl6:Ce (CLYC) scintillation crystals for use in Thermo’s new RadEye SPRD-GN spectroscopic personal radiation detectors.

Thurna ut justo auctor accumsan. Sed velit enim, malesuada nec felis et, ultricies metus donec consectetur bibendum placerat pellentesque malesuada. tellus nibh, vel molestie sapien dapibus.

Newton, MA, August 23, 2016 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received grants totaling $1.86 million under the U.S. Department of Energy’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

Newton, MA, August 17, 2016 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., was selected as a finalist for the R&D 100 awards.

Newton, MA, August 11, 2016 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced its 2016 nine month year to date revenue is $32.9 million compared to $29.8 million in the same nine month period of 2015. This $3.1 million represents an increase of 11% in 2016 primarily driven by our Optics segment businesses.

NEWTON, Mass., June 30, 2016 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ:DYSL) is pleased to announce our new website is now available at www.dynasil.com.

NEWTON, Mass., May 12, 2016 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced a strong revenue showing by its Optics segment. The Optics companies reported revenues of $6.4 million in the quarter ended March 31, 2016 compared to $5.2 million of revenues in the same period of 2015.

NEWTON, Mass., May 10, 2016 Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received six grants totaling $3.8 million under the NASA, National Institute of Health and Department of Energy's funding programs. Read more...

Dynasil Corporation of America (NASDAQ: DYSL), today announced earnings attributable to common stockholders of $106,000 or $0.01 per common share for the first quarter of 2016 fiscal year. Read more...